The Danger Zones : Above 86F (30C) : Rapid protein degradation At or below 32F (0C) : Freezingmedication must be discarded 3236F (02C) : High risk of accidental freezing
In late April, the Food and Drug Administration resolved the Wegovy shortage based on its conclusion that Novo Nordisk is fully meeting current and projected nationwide demand for this medicine
Secondary Outcome: Secondary Outcomes: Changes in waist circumference, body fat, body lean mass, and metabolic risk factors including levels of plasma glucose, insulin sensitivity, serum lipids, and blood pressure Statistical Analysis Full details previously published 2 and can also be found in the STEP group statistical analysis plan at NEJM.org Statistical analysis approach sought strong control for type I error All endpoints addressing intervention efficacy were analyzed using intention-to-treat approach All endpoints addressing intervention safety were analyzed using per-protocol approach Efficacy endpoints analyzed using 2 estimands Treatment Policy Estimand: intention to treat analysis
An adult with a BMI of 32 and sleep apnea receives a denial for incomplete records
PHGG or acacia fiber in small doses (3 to 5 grams) mixed into liquid can provide benefits without significant stomach volume
The FDA has escalated enforcement against compounded GLP-1 marketing since September 2025, Novo Nordisk launched the first FDA-approved oral semaglutide pill in January 2026, and compounding pharmacy supply chains are narrowing as regulatory pressure increases
